Skip Header

You are using a version of browser that may not display all the features of this website. Please consider upgrading your browser.

Real-Time Analysis of Binding Events between Different Abetapisub>1-42pi/sub> Species and Human Lilrb2 by Dual Polarization Interferometry.

Hu T., Wang S., Chen C., Sun J., Yang X.

Abnormal accumulation of 42-residue amyloid-β (Aβ1-42) within the brain triggers the pathogenesis of Alzheimer's disease (AD). In this paper, we use a dual polarization interferometry (DPI) tool to evaluate the binding events of various Aβ1-42 species such as monomeric Aβ1-42, low molecular weight Aβ1-42 oligomer (LMW Aβ1-42), and high molecular weight Aβ1-42 oligomer (HMW Aβ1-42) with extracellular D1D2 domain of lilrb2 (ED1D2L) receptor that has been proved to be associated with AD. Based on the real-time binding information provided by DPI, the association rate (ka) of ED1D2L receptor with monomeric Aβ1-42, LMW Aβ1-42, and HMW Aβ1-42 is individually determined to be 2.85 × 104, 4.52 × 104, and 1.34 × 105 M-1·s-1, and meanwhile, the dissociation rate (kd) corresponds to 1.79 × 10-2, 2.09 × 10-2, and 5.34 × 10-4 s-1, respectively. By analysis of the kinetic parameters of ka and kd values, we discovery that the HMW Aβ1-42 exhibits the fastest rate for ED1D2L receptor in the association phrase, and HMW Aβ1-42 likewise shows the highest affinity with ED1D2L receptor during the dissociation period in contrast to LMW Aβ1-42 and monomeric Aβ1-42. Our findings significantly reveal the different binding behaviors among them from the perspective of kinetics aspect, by which we could indirectly elucidate the malicious impacts in the process of AD triggered by HMW Aβ1-42. Strikingly, this work offers a new exciting clue to explore the dynamic properties associated with interactions of various Aβ1-42 species with other targets and hopefully contributes to drug discovery and screen in the future.

Anal Chem 89:2606-2612(2017) [PubMed] [Europe PMC]

UniProt is an ELIXIR core data resource
Main funding by: National Institutes of Health

We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.

Do not show this banner again